🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. DURVALUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN, ETOPOSIDE, Olaparib, CARBOPLATIN, MK-7339, Olaparib Placebo, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, PEMETREXED, PACLITAXEL

    Merck Sharp and Dohme

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  2. DURVALUMAB, MYCOPHENOLIC ACID , Padcev 20 mg powder for concentrate for solution for infusion, TREMELIMUMAB, Padcev 30 mg powder for concentrate for solution for infusion, INFLIXIMAB

    AstraZeneca AB

    Bladder Cancer

    phase 3 small molecule active

    1 trial

  3. DX-2930

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    3 trials

  4. DX-2930 - 300mg/2wk

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    1 trial

  5. Daclatasvir

    Bristol-Myers Squibb

    Hepatitis C Virus Infection

    phase 3 small molecule completed

    2 trials

  6. Danicopan

    Alexion Europe SAS

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  7. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction

    phase 3 small molecule completed

    1 trial

  8. Dapagliflozin

    AstraZeneca

    Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

    phase 3 small molecule completed

    1 trial

  9. Dapagliflozin

    AstraZeneca

    Heart Failure With Preserved Ejection Fraction (HFpEF)

    phase 3 small molecule completed

    1 trial

  10. Dapagliflozin+Standard Treatment for 12 weeks,washout period for 4 weeks，then Standard Treatment alone for12 weeks

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pediatric Hereditary Kidney Diseases

    phase 3 small molecule active

    1 trial

  11. Dara SC

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  12. Daratumumab

    Janssen Cilag International NV

    Multiple Myeloma

    phase 3 small molecule active

    3 trials

  13. Daratumumab, DARATUMUMAB, LENALIDOMIDE, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE

    Celltrion Healthcare Australia Pty Ltd

    Refractory or Relapsed Multiple Myeloma

    phase 3 small molecule active

    1 trial

  14. Darleukin, Fibromun

    Philogen S.p.A.

    Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions

    phase 3 small molecule active

    1 trial

  15. Darovasertib

    IDEAYA Biosciences

    Uveal Melanoma

    phase 3 small molecule active

    2 trials

  16. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  17. Datopotamab deruxtecan, MYCOPHENOLATE MOFETIL, PEMBROLIZUMAB, INFLIXIMAB, CAPECITABINE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  18. Datopotamab deruxtecan, Rilvegostomig, MYCOPHENOLATE MOFETIL, INFLIXIMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    AstraZeneca AB

    Locally-advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  19. Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, Matching placebo tablets without active substance, Idarubicin Ebewe 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quizartinib, Citarabina Hikma 100mg/5mL Soluzione Iniettabile, Quizartinib

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  20. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The nominal volume in each vial is 5.0 mL. The placebo is aseptically filled into 6R glass vials, stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-toSevere Symptom State

    phase 3 small molecule active

    1 trial

  21. Dazodalibep, The placebo is formulated as sterile liquid intended for intravenous infusion following dilution in normal saline. The placebo is aseptically filled into 6R glass vials( the nominal volume in each vial is 5.0 mL) and 20R glass vials (the nominal volume in each vial is 15.0 mL) , stoppered with a Flurotec-coated elastomeric stopper, and sealed with an aluminum overseal.

    Elan Pharma International

    Sjögren’s Syndrome With Moderate-to-severe Systemic Disease Activity

    phase 3 small molecule active

    1 trial

  22. De-escalation to ticagrelor 60 mg at day 30

    COLLEGIUM PHARMACEUTICAL, INC

    Non ST Segment Elevation Acute Coronary Syndrome

    phase 3 small molecule active

    1 trial

  23. Deferasirox

    Novartis Pharmaceuticals

    Transfusion-dependent Iron Overload

    phase 3 small molecule completed

    1 trial

  24. Deferiprone oral solution

    BRIGHT MINDS BIOSCIENCES INC.

    Pantothenate Kinase-Associated Neurodegeneration

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources